Jan. 16 at 10:39 PM
$ABCL Like holders of
$PLTR &
$NVDA long before us, holding
$ABCL requires guts & patience over a long period. The only quick reward will be a short squeeze, which I see as inevitable before the year is out, given the high short to float of 21%. The clinical trial process is slow and methodical. But in our case, unlike with traditional biopharma, the outcome has high odds for success. That is because we are dealing with unique antibodies, not chemical compounds with a multiplicity of adverse side effects. Bottom line for me: I buy
$ABCL whenever I have
$5 or more in available cash. One share at a time, one day at a time. Such is how fortunes are made.
